Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65-flLAMP DC + GM-CSF
- Development stage
- Unknown
- Lead developer
- Immunomic Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
A cancer vaccine therapy that combines dendritic cells loaded with cytomegalovirus (CMV) pp65 antigen and granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjuvant. The vaccine consists of two main components: 1. **pp65-flLAMP DC**: Autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 fused to the full-length lysosomal-associated membrane protein (LAMP). This fusion enhances activation and expansion of CMV-specific T cells. 2. **GM-CSF (Sargramostim)**: A cytokine stimulating white blood cell growth, particularly granulocytes and macrophages, serving as an adjuvant to enhance the immune response.
- Other names
- autologous CMV-pp65-flLAMP mRNA-loaded dendritic cell vaccine + GM-CSFpp65 DC + GM-CSFCMV pp65 DC vaccine + GM-CSFpp65-LAMP mRNA-pulsed DCs + GM-CSF
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)Cytomegalovirus pp65 peptide-specific T-cell receptor via pp65 peptide:MHC class II complex
Beyond the preview
Go deeper on pp65-flLAMP DC + GM-CSF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65-flLAMP DC + GM-CSF.